Hence, there is an urgent demand to develop new combination of treatment to simultaneously target multiple pathways, and thereby enhancing the efficacy of EGFR-TKI in treating NSCLC, in particular, the EGFR wild-type NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.